4.7 Article

The Pharmacological Potential of Novel Melittin Variants from the Honeybee and Solitary Bees against Inflammation and Cancer

Journal

TOXINS
Volume 14, Issue 12, Pages -

Publisher

MDPI
DOI: 10.3390/toxins14120818

Keywords

venom; melittin; melittin variants; honeybee; solitary bees; inflammation; anti-tumor effect

Funding

  1. Landesoffensive zur Entwicklung wissenschaftlichoekonomischer Exzellenz (LOEWE): The LOEWE Centre for Translational Biodiversity Genomics
  2. LOEWE Centre Novel Drug Targets against Poverty-Related and Neglected Tropical Infectious Diseases (DRUID)
  3. LOEWE Centre for Personalized Translational Epilepsy Research (CePTER)
  4. Leistungszentrum innovative Therapeutics (TheraNova)
  5. Fraunhofer Cluster of Excellence Immune mediated diseases (CIMD)
  6. Innovative Medicines Initiative 2 Joint Undertaking (JU)
  7. European Union's Horizon 2020 research and innovation program [853988]
  8. EFPIA
  9. JDRF INTERNATIONAL
  10. DFG
  11. [RE3454/6-1]

Ask authors/readers for more resources

The venom of honeybees, specifically melittin peptides, has shown potential therapeutic effects on inflammation and cancer. This study explores the pharmacological activities of known and newly discovered melittin variants from honeybees and older solitary bees in the context of cancer and inflammation. The findings suggest that some ancestral variants from solitary bees have promising therapeutic potential in modulating inflammatory processes and inhibiting cancer cell viability/proliferation, including aggressive breast cancers.
The venom of honeybees is composed of numerous peptides and proteins and has been used for decades as an anti-inflammatory and anti-cancer agent in traditional medicine. However, the bioactivity of specific biomolecular components has been evaluated for the predominant constituent, melittin. So far, only a few melittin-like peptides from solitary bee species have been investigated, and the molecular mechanisms of bee venoms as therapeutic agents remain largely unknown. Here, the preclinical pharmacological activities of known and proteo-transcriptomically discovered new melittin variants from the honeybee and more ancestral variants from phylogenetically older solitary bees were explored in the context of cancer and inflammation. We studied the effects of melittin peptides on cytotoxicity, second messenger release, and inflammatory markers using primary human cells, non-cancer, and cancerous cell lines. Melittin and some of its variants showed cytotoxic effects, induced Ca2+ signaling and inhibited cAMP production, and prevented LPS-induced NO synthesis but did not affect the IP3 signaling and pro-inflammatory activation of endothelial cells. Compared to the originally-described melittin, some phylogenetically more ancestral variants from solitary bees offer potential therapeutic modalities in modulating the in vitro inflammatory processes, and hindering cancer cell viability/proliferation, including aggressive breast cancers, and are worth further investigation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available